NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376]

Final Stakeholder list

Consultees	Commentators (no right to submit or appeal)
Company	General
Terumo Europe (QuiremSpheres)	All Wales Therapeutics and Toxicology
, , , , , ,	Centre
Patient/carer groups	Allied Health Professionals Federation
 Black Health Agency for Equality 	Board of Community Health Councils in
British Liver Trust	Wales
Cancer Black Care	British National Formulary
Cancer Equality	Care Quality Commission
• Cancer 52	Department of Health, Social Services
GUTS UK	and Public Safety for Northern Ireland
Haemochromatosis UK	Healthcare Improvement Scotland
Helen Rollason Cancer Charity	Medicines and Healthcare products Pagulatany Agency
Hepatitis B Foundation UK	Regulatory Agency
Hepatitis C Trust Hepatitis C Trust	National Association of Primary Care National Pharmacy Association
Independent Cancer Patients' Voice Independent Cancer Patients' Voice	National Pharmacy AssociationNHS Alliance
Liver4Life Magnillan Canaga Support	NHS Confederation
Macmillan Cancer SupportMaggie's Centres	Scottish Health Technologies Group
Maggle's CentresMarie Curie	Scottish HepatoPancreatoBiliary
Pelican Cancer Foundation	Network
South Asian Health Foundation	Scottish Medicines Consortium
Specialised Healthcare Alliance	Scottish Society of Gastroenterology
Tenovus Cancer Care	Welsh Government
Tonovao Garicon Gare	Welsh Health Specialised Services
Professional groups	Committee
Association of Anaesthetists of Great	
Britain & Ireland	Comparator companies
 Association of Cancer Physicians 	Boston Scientific (TheraSphere)
Association of Surgeons of Great	Sirtex Medical (SIR-Spheres)
Britain & Ireland	Relevant Research groups
British Association for the Study of the Liver	Cochrane Hepatobiliary group
Liver • British Association for the Study of the	Cochrane UK
 British Association for the Study of the Liver Nurses Forum 	Foundation for Liver Research

Stakeholder list for the technology appraisal of selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376] Issue date: December 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

	mmentators (no right to submit or peal)
 British Institute of Radiology British Nuclear Medicine Society British Oncology Pharmacy	Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research sociated Public Health Groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Stakeholder list for the technology appraisal of selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376] Issue date: December 2023

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.

Stakeholder list for the technology appraisal of selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376] Issue date: December 2023